Relypsa, Inc. Announces Closing of Public Offering of Common Stock
GlobeNewswire - Wed Apr 16, 3:00PM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced the closing of its public offering of 4,130,611 shares of its common stock at a price to the public of $24.50 per share for gross proceeds of approximately $101 million, which includes the exercise in full by the underwriters of their option to purchase up to 538,775 additional shares of common stock. Relypsa estimates net proceeds from the offering to be approximately $94 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Nasdaq stocks posting largest percentage decreases
AP - Tue Apr 15, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Relypsa, Inc. Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Thu Apr 10, 10:50PM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced the pricing of an underwritten public offering of 3,591,836 shares of its common stock at a price to the public of $24.50 per share for gross proceeds of approximately $88 million. Relypsa estimates net proceeds from the offering to be approximately $82 million, after deducting underwriting discounts and commissions and estimated offering expenses. In addition, Relypsa has granted the underwriters a 30-day option to purchase up to an additional 538,775 shares of common stock.
Relypsa, Inc. Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Apr 08, 3:05PM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of $80 million. All of the shares of the common stock to be sold in the offering will be offered by Relypsa. In addition, Relypsa intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares sold. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Relypsa Names Sylvia R. Wheeler V.P. Investor Relations and Corporate Affairs
GlobeNewswire - Wed Apr 02, 8:43AM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced the appointment of Sylvia R. Wheeler to the position of Vice President, Investor Relations and Corporate Affairs. Ms. Wheeler, a veteran biopharmaceutical executive, joins Relypsa with over 20 years of experience in investor relations and corporate communications. In her new role, Ms. Wheeler will be a member of the leadership team and will report to John Orwin, President and Chief Executive Officer of Relypsa.
Weakness Seen in Relypsa (RLYP): Stock Plunges 19.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 7:42AM CDT
Relypsa (RLYP) fell over 19% in the last trading session amid high volumes, breaking its recent volatile trend as it is currently trading below the volatile price range of last one month.
Relypsa (RLYP) in Focus: Stock Adds 12.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 8:46AM CDT
Relypsa was a big mover last session, with shares rising over 12% on the day.
Rev Shark: A Messy Day of Action
at The Street - Wed Mar 19, 3:31PM CDT
A few minor changes to Fed policy were enough to spook the market.
Narrower-Than-Expected Loss at Relypsa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 8:20AM CDT
Relypsa reported a loss of 68 cents per share narrower than the Zacks Consensus Estimate of a loss of 74 cents.
Relypsa Announces Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Mon Mar 17, 3:26PM CDT
Relypsa, Inc. (Nasdaq: RLYP), a biopharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2013.
Relypsa to Present at Two Upcoming Investor Conferences in March
GlobeNewswire - Wed Feb 26, 8:22AM CST
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that John Orwin, Chief Executive Officer, will present a corporate overview of the company at the Cowen & Co. 34th Annual Health Care Conference in Boston, MA on March 4 at 10:40 am ET and at the 26th Annual ROTH Conference in Dana Point, CA on March 10 at 5:00 pm PT.
Why Cadence Pharmaceuticals, Relypsa, and Hansen Medical Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 11, 4:15PM CST
You could certainly say that Janet Yellen met or bested expectations in her first testimony to Congress as Federal Reserve chairwoman today, as evidenced by the broad-based rally in the S&P 500 . As my Foolish colleague Travis Hoium noted...